http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 18 May 2026 16:40:49 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Earnings/Evofem+Biosciences+%28EVFM%29+Misses+Q1+EPS+by+4c/26514593.html <p>Evofem Biosciences (OTC: EVFM) reported Q1 EPS of ($0.04). Revenue for the quarter came in at $900 thousand.</p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p>For earnings history and earnings-related data on Evofem Biosciences (EVFM) <a href="http://www.streetinsider.com/ec_earnings.php?q=EVFM">click here</a>.</p> http://www.streetinsider.com/Earnings/Evofem+Biosciences+%28EVFM%29+Misses+Q1+EPS+by+4c/26514593.html Mon, 18 May 2026 16:40:49 -0400 EVFM http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Evofem+Biosciences%2C+Inc.++For%3A+May+18/26510969.html si-local-file:///var/storage/secattach/20260518/26510969.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Evofem+Biosciences%2C+Inc.++For%3A+May+18/26510969.html Mon, 18 May 2026 08:56:00 -0400 EVFM O.07093352 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Evofem+Biosciences%2C+Inc.++For%3A+May+18/26510969.html si-local-file:///var/storage/secattach/20260518/26510969.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Evofem+Biosciences%2C+Inc.++For%3A+May+18/26510969.html Mon, 18 May 2026 08:56:00 -0400 EVFM O.07093352 http://www.streetinsider.com/Press+Releases/Evofem+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26510964.html <p class="bwalignc"> — Advancing Strategy to Increase and Diversify Revenue through Ex-U.S. Commercialization — </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Women’s health innovator <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___http%3A%2Fwww.evofem.com%2F___.YXAzOmV2b2ZlbTpjOm9mZmljZTM2NV9lbWFpbHNfYXR0YWNobWVudDo4NTEzMWEwNWE2ZmY3ZjkyMzljM2UwNjA0NmZmMTdmOTo3OmM2NWI6MGM5Zjc0OTY0ODBjNjBhMzk0MzYzNzExYzcyNWJhZTU3OGYwNWFkNTkwMGQ4ZTAyOTAxYmE2OTQ4ZTg2Y2U5ZjpwOlQ6Rg&amp;esheet=54536557&amp;newsitemid=20260515239050&amp;lan=en-US&amp;anchor=Evofem+Biosciences%2C+Inc.&amp;index=1&amp;md5=846dea82f69ecf1870398bd6d30a2643" shape="rect">Evofem Biosciences, Inc.</a> (Evofem or the Company) (OTCID: EVFM), today announced financial results for the first quarter ended March 31, 2026. </p><p> “Evofem continues to execute our strategy to increase revenues and to diversify and reduce risk in our revenue stream,” said Saundra Pelletier, CEO of Evofem. “A key component of this strategy is commercializing our FDA-approved sexual health products outside the U.S. through strategic alliances such as the ones we have forged for MENA and Sub-Saharan http://www.streetinsider.com/Press+Releases/Evofem+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26510964.html Mon, 18 May 2026 08:55:00 -0400 A.19655944 A.29922014 EVFM O.03307993 O.07093352 O.42081221 http://www.streetinsider.com/Press+Releases/Evofem+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26510964.html <p class="bwalignc"> — Advancing Strategy to Increase and Diversify Revenue through Ex-U.S. Commercialization — </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Women’s health innovator <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___http%3A%2Fwww.evofem.com%2F___.YXAzOmV2b2ZlbTpjOm9mZmljZTM2NV9lbWFpbHNfYXR0YWNobWVudDo4NTEzMWEwNWE2ZmY3ZjkyMzljM2UwNjA0NmZmMTdmOTo3OmM2NWI6MGM5Zjc0OTY0ODBjNjBhMzk0MzYzNzExYzcyNWJhZTU3OGYwNWFkNTkwMGQ4ZTAyOTAxYmE2OTQ4ZTg2Y2U5ZjpwOlQ6Rg&amp;esheet=54536557&amp;newsitemid=20260515239050&amp;lan=en-US&amp;anchor=Evofem+Biosciences%2C+Inc.&amp;index=1&amp;md5=846dea82f69ecf1870398bd6d30a2643" shape="rect">Evofem Biosciences, Inc.</a> (Evofem or the Company) (OTCID: EVFM), today announced financial results for the first quarter ended March 31, 2026. </p><p> “Evofem continues to execute our strategy to increase revenues and to diversify and reduce risk in our revenue stream,” said Saundra Pelletier, CEO of Evofem. “A key component of this strategy is commercializing our FDA-approved sexual health products outside the U.S. through strategic alliances such as the ones we have forged for MENA and Sub-Saharan http://www.streetinsider.com/Press+Releases/Evofem+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26510964.html Mon, 18 May 2026 08:55:00 -0400 A.19655944 A.29922014 EVFM O.03307993 O.07093352 O.42081221 http://www.streetinsider.com/Press+Releases/Evofem+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26510964.html <p class="bwalignc"> — Advancing Strategy to Increase and Diversify Revenue through Ex-U.S. Commercialization — </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Women’s health innovator <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___http%3A%2Fwww.evofem.com%2F___.YXAzOmV2b2ZlbTpjOm9mZmljZTM2NV9lbWFpbHNfYXR0YWNobWVudDo4NTEzMWEwNWE2ZmY3ZjkyMzljM2UwNjA0NmZmMTdmOTo3OmM2NWI6MGM5Zjc0OTY0ODBjNjBhMzk0MzYzNzExYzcyNWJhZTU3OGYwNWFkNTkwMGQ4ZTAyOTAxYmE2OTQ4ZTg2Y2U5ZjpwOlQ6Rg&amp;esheet=54536557&amp;newsitemid=20260515239050&amp;lan=en-US&amp;anchor=Evofem+Biosciences%2C+Inc.&amp;index=1&amp;md5=846dea82f69ecf1870398bd6d30a2643" shape="rect">Evofem Biosciences, Inc.</a> (Evofem or the Company) (OTCID: EVFM), today announced financial results for the first quarter ended March 31, 2026. </p><p> “Evofem continues to execute our strategy to increase revenues and to diversify and reduce risk in our revenue stream,” said Saundra Pelletier, CEO of Evofem. “A key component of this strategy is commercializing our FDA-approved sexual health products outside the U.S. through strategic alliances such as the ones we have forged for MENA and Sub-Saharan http://www.streetinsider.com/Press+Releases/Evofem+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26510964.html Mon, 18 May 2026 08:55:00 -0400 A.19655944 A.29922014 EVFM O.03307993 O.07093352 O.42081221 http://www.streetinsider.com/Press+Releases/Evofem+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26510964.html <p class="bwalignc"> — Advancing Strategy to Increase and Diversify Revenue through Ex-U.S. Commercialization — </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Women’s health innovator <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___http%3A%2Fwww.evofem.com%2F___.YXAzOmV2b2ZlbTpjOm9mZmljZTM2NV9lbWFpbHNfYXR0YWNobWVudDo4NTEzMWEwNWE2ZmY3ZjkyMzljM2UwNjA0NmZmMTdmOTo3OmM2NWI6MGM5Zjc0OTY0ODBjNjBhMzk0MzYzNzExYzcyNWJhZTU3OGYwNWFkNTkwMGQ4ZTAyOTAxYmE2OTQ4ZTg2Y2U5ZjpwOlQ6Rg&amp;esheet=54536557&amp;newsitemid=20260515239050&amp;lan=en-US&amp;anchor=Evofem+Biosciences%2C+Inc.&amp;index=1&amp;md5=846dea82f69ecf1870398bd6d30a2643" shape="rect">Evofem Biosciences, Inc.</a> (Evofem or the Company) (OTCID: EVFM), today announced financial results for the first quarter ended March 31, 2026. </p><p> “Evofem continues to execute our strategy to increase revenues and to diversify and reduce risk in our revenue stream,” said Saundra Pelletier, CEO of Evofem. “A key component of this strategy is commercializing our FDA-approved sexual health products outside the U.S. through strategic alliances such as the ones we have forged for MENA and Sub-Saharan http://www.streetinsider.com/Press+Releases/Evofem+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26510964.html Mon, 18 May 2026 08:55:00 -0400 A.19655944 A.29922014 EVFM O.03307993 O.07093352 O.42081221 http://www.streetinsider.com/Press+Releases/Evofem+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26510964.html <p class="bwalignc"> — Advancing Strategy to Increase and Diversify Revenue through Ex-U.S. Commercialization — </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Women’s health innovator <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___http%3A%2Fwww.evofem.com%2F___.YXAzOmV2b2ZlbTpjOm9mZmljZTM2NV9lbWFpbHNfYXR0YWNobWVudDo4NTEzMWEwNWE2ZmY3ZjkyMzljM2UwNjA0NmZmMTdmOTo3OmM2NWI6MGM5Zjc0OTY0ODBjNjBhMzk0MzYzNzExYzcyNWJhZTU3OGYwNWFkNTkwMGQ4ZTAyOTAxYmE2OTQ4ZTg2Y2U5ZjpwOlQ6Rg&amp;esheet=54536557&amp;newsitemid=20260515239050&amp;lan=en-US&amp;anchor=Evofem+Biosciences%2C+Inc.&amp;index=1&amp;md5=846dea82f69ecf1870398bd6d30a2643" shape="rect">Evofem Biosciences, Inc.</a> (Evofem or the Company) (OTCID: EVFM), today announced financial results for the first quarter ended March 31, 2026. </p><p> “Evofem continues to execute our strategy to increase revenues and to diversify and reduce risk in our revenue stream,” said Saundra Pelletier, CEO of Evofem. “A key component of this strategy is commercializing our FDA-approved sexual health products outside the U.S. through strategic alliances such as the ones we have forged for MENA and Sub-Saharan http://www.streetinsider.com/Press+Releases/Evofem+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26510964.html Mon, 18 May 2026 08:55:00 -0400 A.19655944 A.29922014 EVFM O.03307993 O.07093352 O.42081221 http://www.streetinsider.com/Press+Releases/Evofem+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26510964.html <p class="bwalignc"> — Advancing Strategy to Increase and Diversify Revenue through Ex-U.S. Commercialization — </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Women’s health innovator <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___http%3A%2Fwww.evofem.com%2F___.YXAzOmV2b2ZlbTpjOm9mZmljZTM2NV9lbWFpbHNfYXR0YWNobWVudDo4NTEzMWEwNWE2ZmY3ZjkyMzljM2UwNjA0NmZmMTdmOTo3OmM2NWI6MGM5Zjc0OTY0ODBjNjBhMzk0MzYzNzExYzcyNWJhZTU3OGYwNWFkNTkwMGQ4ZTAyOTAxYmE2OTQ4ZTg2Y2U5ZjpwOlQ6Rg&amp;esheet=54536557&amp;newsitemid=20260515239050&amp;lan=en-US&amp;anchor=Evofem+Biosciences%2C+Inc.&amp;index=1&amp;md5=846dea82f69ecf1870398bd6d30a2643" shape="rect">Evofem Biosciences, Inc.</a> (Evofem or the Company) (OTCID: EVFM), today announced financial results for the first quarter ended March 31, 2026. </p><p> “Evofem continues to execute our strategy to increase revenues and to diversify and reduce risk in our revenue stream,” said Saundra Pelletier, CEO of Evofem. “A key component of this strategy is commercializing our FDA-approved sexual health products outside the U.S. through strategic alliances such as the ones we have forged for MENA and Sub-Saharan http://www.streetinsider.com/Press+Releases/Evofem+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26510964.html Mon, 18 May 2026 08:55:00 -0400 A.19655944 A.29922014 EVFM O.03307993 O.07093352 O.42081221 http://www.streetinsider.com/Business+Wire/Evofem+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26510964.html <p class="bwalignc"> — Advancing Strategy to Increase and Diversify Revenue through Ex-U.S. Commercialization — </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Women’s health innovator <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___http%3A%2Fwww.evofem.com%2F___.YXAzOmV2b2ZlbTpjOm9mZmljZTM2NV9lbWFpbHNfYXR0YWNobWVudDo4NTEzMWEwNWE2ZmY3ZjkyMzljM2UwNjA0NmZmMTdmOTo3OmM2NWI6MGM5Zjc0OTY0ODBjNjBhMzk0MzYzNzExYzcyNWJhZTU3OGYwNWFkNTkwMGQ4ZTAyOTAxYmE2OTQ4ZTg2Y2U5ZjpwOlQ6Rg&amp;esheet=54536557&amp;newsitemid=20260515239050&amp;lan=en-US&amp;anchor=Evofem+Biosciences%2C+Inc.&amp;index=1&amp;md5=846dea82f69ecf1870398bd6d30a2643" shape="rect">Evofem Biosciences, Inc.</a> (Evofem or the Company) (OTCID: EVFM), today announced financial results for the first quarter ended March 31, 2026. </p><p> “Evofem continues to execute our strategy to increase revenues and to diversify and reduce risk in our revenue stream,” said Saundra Pelletier, CEO of Evofem. “A key component of this strategy is commercializing our FDA-approved sexual health products outside the U.S. through strategic alliances such as the ones we have forged for MENA and Sub-Saharan http://www.streetinsider.com/Business+Wire/Evofem+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26510964.html Mon, 18 May 2026 08:55:00 -0400 A.19655944 A.29922014 EVFM O.03307993 O.07093352 O.42081221 http://www.streetinsider.com/Business+Wire/Evofem+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26510964.html <p class="bwalignc"> — Advancing Strategy to Increase and Diversify Revenue through Ex-U.S. Commercialization — </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Women’s health innovator <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___http%3A%2Fwww.evofem.com%2F___.YXAzOmV2b2ZlbTpjOm9mZmljZTM2NV9lbWFpbHNfYXR0YWNobWVudDo4NTEzMWEwNWE2ZmY3ZjkyMzljM2UwNjA0NmZmMTdmOTo3OmM2NWI6MGM5Zjc0OTY0ODBjNjBhMzk0MzYzNzExYzcyNWJhZTU3OGYwNWFkNTkwMGQ4ZTAyOTAxYmE2OTQ4ZTg2Y2U5ZjpwOlQ6Rg&amp;esheet=54536557&amp;newsitemid=20260515239050&amp;lan=en-US&amp;anchor=Evofem+Biosciences%2C+Inc.&amp;index=1&amp;md5=846dea82f69ecf1870398bd6d30a2643" shape="rect">Evofem Biosciences, Inc.</a> (Evofem or the Company) (OTCID: EVFM), today announced financial results for the first quarter ended March 31, 2026. </p><p> “Evofem continues to execute our strategy to increase revenues and to diversify and reduce risk in our revenue stream,” said Saundra Pelletier, CEO of Evofem. “A key component of this strategy is commercializing our FDA-approved sexual health products outside the U.S. through strategic alliances such as the ones we have forged for MENA and Sub-Saharan http://www.streetinsider.com/Business+Wire/Evofem+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26510964.html Mon, 18 May 2026 08:55:00 -0400 A.19655944 A.29922014 EVFM O.03307993 O.07093352 O.42081221 http://www.streetinsider.com/Business+Wire/Evofem+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26510964.html <p class="bwalignc"> — Advancing Strategy to Increase and Diversify Revenue through Ex-U.S. Commercialization — </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Women’s health innovator <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___http%3A%2Fwww.evofem.com%2F___.YXAzOmV2b2ZlbTpjOm9mZmljZTM2NV9lbWFpbHNfYXR0YWNobWVudDo4NTEzMWEwNWE2ZmY3ZjkyMzljM2UwNjA0NmZmMTdmOTo3OmM2NWI6MGM5Zjc0OTY0ODBjNjBhMzk0MzYzNzExYzcyNWJhZTU3OGYwNWFkNTkwMGQ4ZTAyOTAxYmE2OTQ4ZTg2Y2U5ZjpwOlQ6Rg&amp;esheet=54536557&amp;newsitemid=20260515239050&amp;lan=en-US&amp;anchor=Evofem+Biosciences%2C+Inc.&amp;index=1&amp;md5=846dea82f69ecf1870398bd6d30a2643" shape="rect">Evofem Biosciences, Inc.</a> (Evofem or the Company) (OTCID: EVFM), today announced financial results for the first quarter ended March 31, 2026. </p><p> “Evofem continues to execute our strategy to increase revenues and to diversify and reduce risk in our revenue stream,” said Saundra Pelletier, CEO of Evofem. “A key component of this strategy is commercializing our FDA-approved sexual health products outside the U.S. through strategic alliances such as the ones we have forged for MENA and Sub-Saharan http://www.streetinsider.com/Business+Wire/Evofem+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26510964.html Mon, 18 May 2026 08:55:00 -0400 A.19655944 A.29922014 EVFM O.03307993 O.07093352 O.42081221 http://www.streetinsider.com/Business+Wire/Evofem+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26510964.html <p class="bwalignc"> — Advancing Strategy to Increase and Diversify Revenue through Ex-U.S. Commercialization — </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Women’s health innovator <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___http%3A%2Fwww.evofem.com%2F___.YXAzOmV2b2ZlbTpjOm9mZmljZTM2NV9lbWFpbHNfYXR0YWNobWVudDo4NTEzMWEwNWE2ZmY3ZjkyMzljM2UwNjA0NmZmMTdmOTo3OmM2NWI6MGM5Zjc0OTY0ODBjNjBhMzk0MzYzNzExYzcyNWJhZTU3OGYwNWFkNTkwMGQ4ZTAyOTAxYmE2OTQ4ZTg2Y2U5ZjpwOlQ6Rg&amp;esheet=54536557&amp;newsitemid=20260515239050&amp;lan=en-US&amp;anchor=Evofem+Biosciences%2C+Inc.&amp;index=1&amp;md5=846dea82f69ecf1870398bd6d30a2643" shape="rect">Evofem Biosciences, Inc.</a> (Evofem or the Company) (OTCID: EVFM), today announced financial results for the first quarter ended March 31, 2026. </p><p> “Evofem continues to execute our strategy to increase revenues and to diversify and reduce risk in our revenue stream,” said Saundra Pelletier, CEO of Evofem. “A key component of this strategy is commercializing our FDA-approved sexual health products outside the U.S. through strategic alliances such as the ones we have forged for MENA and Sub-Saharan http://www.streetinsider.com/Business+Wire/Evofem+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26510964.html Mon, 18 May 2026 08:55:00 -0400 A.19655944 A.29922014 EVFM O.03307993 O.07093352 O.42081221 http://www.streetinsider.com/Business+Wire/Evofem+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26510964.html <p class="bwalignc"> — Advancing Strategy to Increase and Diversify Revenue through Ex-U.S. Commercialization — </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Women’s health innovator <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___http%3A%2Fwww.evofem.com%2F___.YXAzOmV2b2ZlbTpjOm9mZmljZTM2NV9lbWFpbHNfYXR0YWNobWVudDo4NTEzMWEwNWE2ZmY3ZjkyMzljM2UwNjA0NmZmMTdmOTo3OmM2NWI6MGM5Zjc0OTY0ODBjNjBhMzk0MzYzNzExYzcyNWJhZTU3OGYwNWFkNTkwMGQ4ZTAyOTAxYmE2OTQ4ZTg2Y2U5ZjpwOlQ6Rg&amp;esheet=54536557&amp;newsitemid=20260515239050&amp;lan=en-US&amp;anchor=Evofem+Biosciences%2C+Inc.&amp;index=1&amp;md5=846dea82f69ecf1870398bd6d30a2643" shape="rect">Evofem Biosciences, Inc.</a> (Evofem or the Company) (OTCID: EVFM), today announced financial results for the first quarter ended March 31, 2026. </p><p> “Evofem continues to execute our strategy to increase revenues and to diversify and reduce risk in our revenue stream,” said Saundra Pelletier, CEO of Evofem. “A key component of this strategy is commercializing our FDA-approved sexual health products outside the U.S. through strategic alliances such as the ones we have forged for MENA and Sub-Saharan http://www.streetinsider.com/Business+Wire/Evofem+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26510964.html Mon, 18 May 2026 08:55:00 -0400 A.19655944 A.29922014 EVFM O.03307993 O.07093352 O.42081221 http://www.streetinsider.com/Business+Wire/Evofem+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26510964.html <p class="bwalignc"> — Advancing Strategy to Increase and Diversify Revenue through Ex-U.S. Commercialization — </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Women’s health innovator <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___http%3A%2Fwww.evofem.com%2F___.YXAzOmV2b2ZlbTpjOm9mZmljZTM2NV9lbWFpbHNfYXR0YWNobWVudDo4NTEzMWEwNWE2ZmY3ZjkyMzljM2UwNjA0NmZmMTdmOTo3OmM2NWI6MGM5Zjc0OTY0ODBjNjBhMzk0MzYzNzExYzcyNWJhZTU3OGYwNWFkNTkwMGQ4ZTAyOTAxYmE2OTQ4ZTg2Y2U5ZjpwOlQ6Rg&amp;esheet=54536557&amp;newsitemid=20260515239050&amp;lan=en-US&amp;anchor=Evofem+Biosciences%2C+Inc.&amp;index=1&amp;md5=846dea82f69ecf1870398bd6d30a2643" shape="rect">Evofem Biosciences, Inc.</a> (Evofem or the Company) (OTCID: EVFM), today announced financial results for the first quarter ended March 31, 2026. </p><p> “Evofem continues to execute our strategy to increase revenues and to diversify and reduce risk in our revenue stream,” said Saundra Pelletier, CEO of Evofem. “A key component of this strategy is commercializing our FDA-approved sexual health products outside the U.S. through strategic alliances such as the ones we have forged for MENA and Sub-Saharan http://www.streetinsider.com/Business+Wire/Evofem+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26510964.html Mon, 18 May 2026 08:55:00 -0400 A.19655944 A.29922014 EVFM O.03307993 O.07093352 O.42081221 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Evofem+Biosciences%2C+Inc.++For%3A+Mar+31/26507645.html si-local-file:///var/storage/secattach/20260515/26507645.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Evofem+Biosciences%2C+Inc.++For%3A+Mar+31/26507645.html Fri, 15 May 2026 17:05:00 -0400 EVFM O.07093352 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Evofem+Biosciences%2C+Inc.++For%3A+Mar+31/26507645.html si-local-file:///var/storage/secattach/20260515/26507645.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Evofem+Biosciences%2C+Inc.++For%3A+Mar+31/26507645.html Fri, 15 May 2026 17:05:00 -0400 EVFM O.07093352 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Evofem+Biosciences%2C+Inc.++For%3A+Apr+24/26407710.html si-local-file:///var/storage/secattach/20260430/26407710.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Evofem+Biosciences%2C+Inc.++For%3A+Apr+24/26407710.html Thu, 30 Apr 2026 16:06:00 -0400 EVFM O.07093352 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Evofem+Biosciences%2C+Inc.++For%3A+Apr+24/26407710.html si-local-file:///var/storage/secattach/20260430/26407710.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Evofem+Biosciences%2C+Inc.++For%3A+Apr+24/26407710.html Thu, 30 Apr 2026 16:06:00 -0400 EVFM O.07093352 http://www.streetinsider.com/Press+Releases/Evofem+Announces+Exclusive+Agreement+for+the+Distribution+and+Commercialization+of+SOLOSEC+in+Sub-Saharan+Africa/26371132.html <p class="bwalignc"> <i><b>— SOLOSEC® (secnidazole) 2g Oral Granules is an FDA-Approved </b></i><b><i>Single-Dose Oral Treatment for Bacterial Vaginosis and Trichomoniasis —</i></b> </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Women’s health innovator <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___http%3A%2Fwww.evofem.com%2F___.YXAzOmV2b2ZlbTpjOm9mZmljZTM2NV9lbWFpbHNfYXR0YWNobWVudDoxMDM3YjgxNmFkZTNjMjg2NjNhOWYxYTMzMTdiMmQ2OTo3OjNmN2M6YjZlNTBjNmQ4MGFhYjYyODM3M2NlZjhmZGQyZGYwMmFlYWQ4ZGM3ZDE1ZWViYTcxOWQ5MGQ4NTYyMmIyM2ZkZDpwOlQ6Rg&amp;esheet=54523055&amp;newsitemid=20260427079872&amp;lan=en-US&amp;anchor=Evofem+Biosciences%2C+Inc.&amp;index=1&amp;md5=2c335ce60685511db7b6596b30301730" shape="rect">Evofem Biosciences, Inc.</a> (OTCID: EVFM) (Evofem or the Company) today announced that it has entered into an exclusive Distribution Agreement with <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___https%3A%2Fclovisdavis.com%2F___.YXAzOmV2b2ZlbTpjOm9mZmljZTM2NV9lbWFpbHNfYXR0YWNobWVudDoxMDM3YjgxNmFkZTNjMjg2NjNhOWYxYTMzMTdiMmQ2OTo3OmM3ZmY6MGRlYmY5MWE4N2EwYWRhY2ZhNjg2M2UxMDc2NTQzMWFkODBhMzMyYjlmMjMwNjJlY2VlZjQ2NjZkOWYzNWJlNDpwOlQ6Rg&amp;esheet=54523055&amp;newsitemid=20260427079872&amp;lan=en-US&amp;anchor=Clovis+Davis+Pharmaceuticals%2C+LLC&amp;index=2&amp;md5=6f3f1dbe47ff26aaa3bb02dd55612a28" shape="rect">Clovis Davis Pharmaceuticals, LLC</a>, a distributor of pharmaceutical and related products (Clovis Davis), to commercialize <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___http%3A%2Fwww.solosec.com%2F___.YXAzOmV2b2ZlbTpjOm9mZmljZTM2NV9lbWFpbHNfYXR0YWNobWVudDoxMDM3YjgxNmFkZTNjMjg2NjNhOWYxYTMzMTdiMmQ2OTo3Ojg2M2U6MGFiYWM2NjdjYjRhZjcyYTU3OWJjMmRiZTQxMGNiMjc0MzY5ZTM3ODQ4Zjk1ZTI3N2QxMDYyYmJjMmRiNjlhNjpwOlQ6Rg&amp;esheet=54523055&amp;newsitemid=20260427079872&amp;lan=en-US&amp;anchor=SOLOSEC%26%23174%3B+%28secnidazole%29+2g+oral+granules&amp;index=3&amp;md5=e34bcd83acacba117e3018a4f7bfb8a3" shape="rect">SOLOSEC® (secnidazole) 2g oral granules</a> in sub-Saharan Africa (the Territory). </p><p> SOLOSEC is approved by the U.S. Food and Drug Administration (FDA) for the treatment of bacterial http://www.streetinsider.com/Press+Releases/Evofem+Announces+Exclusive+Agreement+for+the+Distribution+and+Commercialization+of+SOLOSEC+in+Sub-Saharan+Africa/26371132.html Mon, 27 Apr 2026 09:25:00 -0400 A.06822034 A.17568957 EVFM O.04889877 O.07093352 O.20026344 http://www.streetinsider.com/Press+Releases/Evofem+Announces+Exclusive+Agreement+for+the+Distribution+and+Commercialization+of+SOLOSEC+in+Sub-Saharan+Africa/26371132.html <p class="bwalignc"> <i><b>— SOLOSEC® (secnidazole) 2g Oral Granules is an FDA-Approved </b></i><b><i>Single-Dose Oral Treatment for Bacterial Vaginosis and Trichomoniasis —</i></b> </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Women’s health innovator <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___http%3A%2Fwww.evofem.com%2F___.YXAzOmV2b2ZlbTpjOm9mZmljZTM2NV9lbWFpbHNfYXR0YWNobWVudDoxMDM3YjgxNmFkZTNjMjg2NjNhOWYxYTMzMTdiMmQ2OTo3OjNmN2M6YjZlNTBjNmQ4MGFhYjYyODM3M2NlZjhmZGQyZGYwMmFlYWQ4ZGM3ZDE1ZWViYTcxOWQ5MGQ4NTYyMmIyM2ZkZDpwOlQ6Rg&amp;esheet=54523055&amp;newsitemid=20260427079872&amp;lan=en-US&amp;anchor=Evofem+Biosciences%2C+Inc.&amp;index=1&amp;md5=2c335ce60685511db7b6596b30301730" shape="rect">Evofem Biosciences, Inc.</a> (OTCID: EVFM) (Evofem or the Company) today announced that it has entered into an exclusive Distribution Agreement with <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___https%3A%2Fclovisdavis.com%2F___.YXAzOmV2b2ZlbTpjOm9mZmljZTM2NV9lbWFpbHNfYXR0YWNobWVudDoxMDM3YjgxNmFkZTNjMjg2NjNhOWYxYTMzMTdiMmQ2OTo3OmM3ZmY6MGRlYmY5MWE4N2EwYWRhY2ZhNjg2M2UxMDc2NTQzMWFkODBhMzMyYjlmMjMwNjJlY2VlZjQ2NjZkOWYzNWJlNDpwOlQ6Rg&amp;esheet=54523055&amp;newsitemid=20260427079872&amp;lan=en-US&amp;anchor=Clovis+Davis+Pharmaceuticals%2C+LLC&amp;index=2&amp;md5=6f3f1dbe47ff26aaa3bb02dd55612a28" shape="rect">Clovis Davis Pharmaceuticals, LLC</a>, a distributor of pharmaceutical and related products (Clovis Davis), to commercialize <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___http%3A%2Fwww.solosec.com%2F___.YXAzOmV2b2ZlbTpjOm9mZmljZTM2NV9lbWFpbHNfYXR0YWNobWVudDoxMDM3YjgxNmFkZTNjMjg2NjNhOWYxYTMzMTdiMmQ2OTo3Ojg2M2U6MGFiYWM2NjdjYjRhZjcyYTU3OWJjMmRiZTQxMGNiMjc0MzY5ZTM3ODQ4Zjk1ZTI3N2QxMDYyYmJjMmRiNjlhNjpwOlQ6Rg&amp;esheet=54523055&amp;newsitemid=20260427079872&amp;lan=en-US&amp;anchor=SOLOSEC%26%23174%3B+%28secnidazole%29+2g+oral+granules&amp;index=3&amp;md5=e34bcd83acacba117e3018a4f7bfb8a3" shape="rect">SOLOSEC® (secnidazole) 2g oral granules</a> in sub-Saharan Africa (the Territory). </p><p> SOLOSEC is approved by the U.S. Food and Drug Administration (FDA) for the treatment of bacterial http://www.streetinsider.com/Press+Releases/Evofem+Announces+Exclusive+Agreement+for+the+Distribution+and+Commercialization+of+SOLOSEC+in+Sub-Saharan+Africa/26371132.html Mon, 27 Apr 2026 09:25:00 -0400 A.06822034 A.17568957 EVFM O.04889877 O.07093352 O.20026344 http://www.streetinsider.com/Press+Releases/Evofem+Announces+Exclusive+Agreement+for+the+Distribution+and+Commercialization+of+SOLOSEC+in+Sub-Saharan+Africa/26371132.html <p class="bwalignc"> <i><b>— SOLOSEC® (secnidazole) 2g Oral Granules is an FDA-Approved </b></i><b><i>Single-Dose Oral Treatment for Bacterial Vaginosis and Trichomoniasis —</i></b> </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Women’s health innovator <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___http%3A%2Fwww.evofem.com%2F___.YXAzOmV2b2ZlbTpjOm9mZmljZTM2NV9lbWFpbHNfYXR0YWNobWVudDoxMDM3YjgxNmFkZTNjMjg2NjNhOWYxYTMzMTdiMmQ2OTo3OjNmN2M6YjZlNTBjNmQ4MGFhYjYyODM3M2NlZjhmZGQyZGYwMmFlYWQ4ZGM3ZDE1ZWViYTcxOWQ5MGQ4NTYyMmIyM2ZkZDpwOlQ6Rg&amp;esheet=54523055&amp;newsitemid=20260427079872&amp;lan=en-US&amp;anchor=Evofem+Biosciences%2C+Inc.&amp;index=1&amp;md5=2c335ce60685511db7b6596b30301730" shape="rect">Evofem Biosciences, Inc.</a> (OTCID: EVFM) (Evofem or the Company) today announced that it has entered into an exclusive Distribution Agreement with <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___https%3A%2Fclovisdavis.com%2F___.YXAzOmV2b2ZlbTpjOm9mZmljZTM2NV9lbWFpbHNfYXR0YWNobWVudDoxMDM3YjgxNmFkZTNjMjg2NjNhOWYxYTMzMTdiMmQ2OTo3OmM3ZmY6MGRlYmY5MWE4N2EwYWRhY2ZhNjg2M2UxMDc2NTQzMWFkODBhMzMyYjlmMjMwNjJlY2VlZjQ2NjZkOWYzNWJlNDpwOlQ6Rg&amp;esheet=54523055&amp;newsitemid=20260427079872&amp;lan=en-US&amp;anchor=Clovis+Davis+Pharmaceuticals%2C+LLC&amp;index=2&amp;md5=6f3f1dbe47ff26aaa3bb02dd55612a28" shape="rect">Clovis Davis Pharmaceuticals, LLC</a>, a distributor of pharmaceutical and related products (Clovis Davis), to commercialize <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___http%3A%2Fwww.solosec.com%2F___.YXAzOmV2b2ZlbTpjOm9mZmljZTM2NV9lbWFpbHNfYXR0YWNobWVudDoxMDM3YjgxNmFkZTNjMjg2NjNhOWYxYTMzMTdiMmQ2OTo3Ojg2M2U6MGFiYWM2NjdjYjRhZjcyYTU3OWJjMmRiZTQxMGNiMjc0MzY5ZTM3ODQ4Zjk1ZTI3N2QxMDYyYmJjMmRiNjlhNjpwOlQ6Rg&amp;esheet=54523055&amp;newsitemid=20260427079872&amp;lan=en-US&amp;anchor=SOLOSEC%26%23174%3B+%28secnidazole%29+2g+oral+granules&amp;index=3&amp;md5=e34bcd83acacba117e3018a4f7bfb8a3" shape="rect">SOLOSEC® (secnidazole) 2g oral granules</a> in sub-Saharan Africa (the Territory). </p><p> SOLOSEC is approved by the U.S. Food and Drug Administration (FDA) for the treatment of bacterial http://www.streetinsider.com/Press+Releases/Evofem+Announces+Exclusive+Agreement+for+the+Distribution+and+Commercialization+of+SOLOSEC+in+Sub-Saharan+Africa/26371132.html Mon, 27 Apr 2026 09:25:00 -0400 A.06822034 A.17568957 EVFM O.04889877 O.07093352 O.20026344 http://www.streetinsider.com/Press+Releases/Evofem+Announces+Exclusive+Agreement+for+the+Distribution+and+Commercialization+of+SOLOSEC+in+Sub-Saharan+Africa/26371132.html <p class="bwalignc"> <i><b>— SOLOSEC® (secnidazole) 2g Oral Granules is an FDA-Approved </b></i><b><i>Single-Dose Oral Treatment for Bacterial Vaginosis and Trichomoniasis —</i></b> </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Women’s health innovator <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___http%3A%2Fwww.evofem.com%2F___.YXAzOmV2b2ZlbTpjOm9mZmljZTM2NV9lbWFpbHNfYXR0YWNobWVudDoxMDM3YjgxNmFkZTNjMjg2NjNhOWYxYTMzMTdiMmQ2OTo3OjNmN2M6YjZlNTBjNmQ4MGFhYjYyODM3M2NlZjhmZGQyZGYwMmFlYWQ4ZGM3ZDE1ZWViYTcxOWQ5MGQ4NTYyMmIyM2ZkZDpwOlQ6Rg&amp;esheet=54523055&amp;newsitemid=20260427079872&amp;lan=en-US&amp;anchor=Evofem+Biosciences%2C+Inc.&amp;index=1&amp;md5=2c335ce60685511db7b6596b30301730" shape="rect">Evofem Biosciences, Inc.</a> (OTCID: EVFM) (Evofem or the Company) today announced that it has entered into an exclusive Distribution Agreement with <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___https%3A%2Fclovisdavis.com%2F___.YXAzOmV2b2ZlbTpjOm9mZmljZTM2NV9lbWFpbHNfYXR0YWNobWVudDoxMDM3YjgxNmFkZTNjMjg2NjNhOWYxYTMzMTdiMmQ2OTo3OmM3ZmY6MGRlYmY5MWE4N2EwYWRhY2ZhNjg2M2UxMDc2NTQzMWFkODBhMzMyYjlmMjMwNjJlY2VlZjQ2NjZkOWYzNWJlNDpwOlQ6Rg&amp;esheet=54523055&amp;newsitemid=20260427079872&amp;lan=en-US&amp;anchor=Clovis+Davis+Pharmaceuticals%2C+LLC&amp;index=2&amp;md5=6f3f1dbe47ff26aaa3bb02dd55612a28" shape="rect">Clovis Davis Pharmaceuticals, LLC</a>, a distributor of pharmaceutical and related products (Clovis Davis), to commercialize <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___http%3A%2Fwww.solosec.com%2F___.YXAzOmV2b2ZlbTpjOm9mZmljZTM2NV9lbWFpbHNfYXR0YWNobWVudDoxMDM3YjgxNmFkZTNjMjg2NjNhOWYxYTMzMTdiMmQ2OTo3Ojg2M2U6MGFiYWM2NjdjYjRhZjcyYTU3OWJjMmRiZTQxMGNiMjc0MzY5ZTM3ODQ4Zjk1ZTI3N2QxMDYyYmJjMmRiNjlhNjpwOlQ6Rg&amp;esheet=54523055&amp;newsitemid=20260427079872&amp;lan=en-US&amp;anchor=SOLOSEC%26%23174%3B+%28secnidazole%29+2g+oral+granules&amp;index=3&amp;md5=e34bcd83acacba117e3018a4f7bfb8a3" shape="rect">SOLOSEC® (secnidazole) 2g oral granules</a> in sub-Saharan Africa (the Territory). </p><p> SOLOSEC is approved by the U.S. Food and Drug Administration (FDA) for the treatment of bacterial http://www.streetinsider.com/Press+Releases/Evofem+Announces+Exclusive+Agreement+for+the+Distribution+and+Commercialization+of+SOLOSEC+in+Sub-Saharan+Africa/26371132.html Mon, 27 Apr 2026 09:25:00 -0400 A.06822034 A.17568957 EVFM O.04889877 O.07093352 O.20026344 http://www.streetinsider.com/Press+Releases/Evofem+Announces+Exclusive+Agreement+for+the+Distribution+and+Commercialization+of+SOLOSEC+in+Sub-Saharan+Africa/26371132.html <p class="bwalignc"> <i><b>— SOLOSEC® (secnidazole) 2g Oral Granules is an FDA-Approved </b></i><b><i>Single-Dose Oral Treatment for Bacterial Vaginosis and Trichomoniasis —</i></b> </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Women’s health innovator <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___http%3A%2Fwww.evofem.com%2F___.YXAzOmV2b2ZlbTpjOm9mZmljZTM2NV9lbWFpbHNfYXR0YWNobWVudDoxMDM3YjgxNmFkZTNjMjg2NjNhOWYxYTMzMTdiMmQ2OTo3OjNmN2M6YjZlNTBjNmQ4MGFhYjYyODM3M2NlZjhmZGQyZGYwMmFlYWQ4ZGM3ZDE1ZWViYTcxOWQ5MGQ4NTYyMmIyM2ZkZDpwOlQ6Rg&amp;esheet=54523055&amp;newsitemid=20260427079872&amp;lan=en-US&amp;anchor=Evofem+Biosciences%2C+Inc.&amp;index=1&amp;md5=2c335ce60685511db7b6596b30301730" shape="rect">Evofem Biosciences, Inc.</a> (OTCID: EVFM) (Evofem or the Company) today announced that it has entered into an exclusive Distribution Agreement with <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___https%3A%2Fclovisdavis.com%2F___.YXAzOmV2b2ZlbTpjOm9mZmljZTM2NV9lbWFpbHNfYXR0YWNobWVudDoxMDM3YjgxNmFkZTNjMjg2NjNhOWYxYTMzMTdiMmQ2OTo3OmM3ZmY6MGRlYmY5MWE4N2EwYWRhY2ZhNjg2M2UxMDc2NTQzMWFkODBhMzMyYjlmMjMwNjJlY2VlZjQ2NjZkOWYzNWJlNDpwOlQ6Rg&amp;esheet=54523055&amp;newsitemid=20260427079872&amp;lan=en-US&amp;anchor=Clovis+Davis+Pharmaceuticals%2C+LLC&amp;index=2&amp;md5=6f3f1dbe47ff26aaa3bb02dd55612a28" shape="rect">Clovis Davis Pharmaceuticals, LLC</a>, a distributor of pharmaceutical and related products (Clovis Davis), to commercialize <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___http%3A%2Fwww.solosec.com%2F___.YXAzOmV2b2ZlbTpjOm9mZmljZTM2NV9lbWFpbHNfYXR0YWNobWVudDoxMDM3YjgxNmFkZTNjMjg2NjNhOWYxYTMzMTdiMmQ2OTo3Ojg2M2U6MGFiYWM2NjdjYjRhZjcyYTU3OWJjMmRiZTQxMGNiMjc0MzY5ZTM3ODQ4Zjk1ZTI3N2QxMDYyYmJjMmRiNjlhNjpwOlQ6Rg&amp;esheet=54523055&amp;newsitemid=20260427079872&amp;lan=en-US&amp;anchor=SOLOSEC%26%23174%3B+%28secnidazole%29+2g+oral+granules&amp;index=3&amp;md5=e34bcd83acacba117e3018a4f7bfb8a3" shape="rect">SOLOSEC® (secnidazole) 2g oral granules</a> in sub-Saharan Africa (the Territory). </p><p> SOLOSEC is approved by the U.S. Food and Drug Administration (FDA) for the treatment of bacterial http://www.streetinsider.com/Press+Releases/Evofem+Announces+Exclusive+Agreement+for+the+Distribution+and+Commercialization+of+SOLOSEC+in+Sub-Saharan+Africa/26371132.html Mon, 27 Apr 2026 09:25:00 -0400 A.06822034 A.17568957 EVFM O.04889877 O.07093352 O.20026344 http://www.streetinsider.com/Press+Releases/Evofem+Announces+Exclusive+Agreement+for+the+Distribution+and+Commercialization+of+SOLOSEC+in+Sub-Saharan+Africa/26371132.html <p class="bwalignc"> <i><b>— SOLOSEC® (secnidazole) 2g Oral Granules is an FDA-Approved </b></i><b><i>Single-Dose Oral Treatment for Bacterial Vaginosis and Trichomoniasis —</i></b> </p> <p> SAN DIEGO--(BUSINESS WIRE)-- Women’s health innovator <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___http%3A%2Fwww.evofem.com%2F___.YXAzOmV2b2ZlbTpjOm9mZmljZTM2NV9lbWFpbHNfYXR0YWNobWVudDoxMDM3YjgxNmFkZTNjMjg2NjNhOWYxYTMzMTdiMmQ2OTo3OjNmN2M6YjZlNTBjNmQ4MGFhYjYyODM3M2NlZjhmZGQyZGYwMmFlYWQ4ZGM3ZDE1ZWViYTcxOWQ5MGQ4NTYyMmIyM2ZkZDpwOlQ6Rg&amp;esheet=54523055&amp;newsitemid=20260427079872&amp;lan=en-US&amp;anchor=Evofem+Biosciences%2C+Inc.&amp;index=1&amp;md5=2c335ce60685511db7b6596b30301730" shape="rect">Evofem Biosciences, Inc.</a> (OTCID: EVFM) (Evofem or the Company) today announced that it has entered into an exclusive Distribution Agreement with <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___https%3A%2Fclovisdavis.com%2F___.YXAzOmV2b2ZlbTpjOm9mZmljZTM2NV9lbWFpbHNfYXR0YWNobWVudDoxMDM3YjgxNmFkZTNjMjg2NjNhOWYxYTMzMTdiMmQ2OTo3OmM3ZmY6MGRlYmY5MWE4N2EwYWRhY2ZhNjg2M2UxMDc2NTQzMWFkODBhMzMyYjlmMjMwNjJlY2VlZjQ2NjZkOWYzNWJlNDpwOlQ6Rg&amp;esheet=54523055&amp;newsitemid=20260427079872&amp;lan=en-US&amp;anchor=Clovis+Davis+Pharmaceuticals%2C+LLC&amp;index=2&amp;md5=6f3f1dbe47ff26aaa3bb02dd55612a28" shape="rect">Clovis Davis Pharmaceuticals, LLC</a>, a distributor of pharmaceutical and related products (Clovis Davis), to commercialize <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___http%3A%2Fwww.solosec.com%2F___.YXAzOmV2b2ZlbTpjOm9mZmljZTM2NV9lbWFpbHNfYXR0YWNobWVudDoxMDM3YjgxNmFkZTNjMjg2NjNhOWYxYTMzMTdiMmQ2OTo3Ojg2M2U6MGFiYWM2NjdjYjRhZjcyYTU3OWJjMmRiZTQxMGNiMjc0MzY5ZTM3ODQ4Zjk1ZTI3N2QxMDYyYmJjMmRiNjlhNjpwOlQ6Rg&amp;esheet=54523055&amp;newsitemid=20260427079872&amp;lan=en-US&amp;anchor=SOLOSEC%26%23174%3B+%28secnidazole%29+2g+oral+granules&amp;index=3&amp;md5=e34bcd83acacba117e3018a4f7bfb8a3" shape="rect">SOLOSEC® (secnidazole) 2g oral granules</a> in sub-Saharan Africa (the Territory). </p><p> SOLOSEC is approved by the U.S. Food and Drug Administration (FDA) for the treatment of bacterial http://www.streetinsider.com/Press+Releases/Evofem+Announces+Exclusive+Agreement+for+the+Distribution+and+Commercialization+of+SOLOSEC+in+Sub-Saharan+Africa/26371132.html Mon, 27 Apr 2026 09:25:00 -0400 A.06822034 A.17568957 EVFM O.04889877 O.07093352 O.20026344